论文部分内容阅读
目的检测三磷酸腺苷结合盒转运体A3(ABCA3)基因在急性髓系白血病(AML)细胞中的表达,探讨ABCA3在AML耐药方面的作用及临床意义。方法①应用半定量RT-PCR检测33例初治、13例复发/难治成人AML患者及10例正常对照者骨髓单个核细胞ABCA3 mRNA的表达水平,并分析其在不同组间的表达规律;②将初治AML患者按化疗效果分为完全缓解组和未完全缓解组,比较两组间ABCA3的表达水平;③分析ABCA3与AML患者初诊白细胞数、免疫表型、FAB分型等临床特征之间的相关性。结果 ABCA3的表达水平:初治及复发/难治AML组均明显高于正常对照组(P均<0.01);复发/难治AML组高于初治组(P<0.05);完全缓解组低于未完全缓解组(P<0.05);慢性粒细胞白血病急变患者高于其他AML亚型(除M3外,P均<0.05)。ABCA3的表达水平与AML患者初诊白细胞数、骨髓原始细胞百分数、免疫表型、性别及年龄无明显相关性。结论 ABCA3与AML患者的多药耐药及治疗、预后密切相关。
Objective To detect the expression of adenosine triphosphate binding cassette transporter A3 (ABCA3) gene in acute myeloid leukemia (AML) cells and to explore the role and clinical significance of ABCA3 in resistance to AML. Methods ① The expression of ABCA3 mRNA in bone marrow mononuclear cells from 33 newly diagnosed, 13 recurrent / refractory adult AML patients and 10 normal controls were detected by semi-quantitative RT-PCR. The expression of ABCA3 mRNA in different groups was analyzed. ② The patients with newly diagnosed AML were divided into complete remission group and incomplete remission group according to the chemotherapy effect, and the expression level of ABCA3 was compared between the two groups. ③The clinical features of newly diagnosed ABCA3 and AML patients such as leucocyte count, immunophenotype and FAB typing Relevance between. Results The expression level of ABCA3 in primary and relapsed / refractory AML group was significantly higher than that in normal control group (all P <0.01), that in relapsed / refractory AML group was significantly higher than that in initial treatment group (P <0.05), and that in complete remission group (P <0.05). Patients with chronic myeloid leukemia were more severe than those with other AML subtypes (P <0.05, except M3). ABCA3 expression levels and AML patients newly diagnosed leukocytes, bone marrow blast cell percentage, immunophenotype, gender and age no significant correlation. Conclusions ABCA3 and AML patients are closely related to multi-drug resistance, treatment and prognosis.